Amylyx Pharmaceuticals annual capital expenditures (capex)
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Capital Expenditures (CapEx) Growth & History (AMLX)
Amylyx Pharmaceuticals's capital expenditures (capex) was $138,000 for fiscal 2025.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $138,000 | −$19,000 | −12.10% |
| 2024 | 2024-12-31 | $157,000 | −$1.1M | −87.35% |
| 2023 | 2023-12-31 | $1.2M | −$1.3M | −50.87% |
| 2022 | 2022-12-31 | $2.5M | $2.2M | +615.58% |
| 2021 | 2021-12-31 | $353,000 | — | — |
Amylyx Pharmaceuticals quarterly capital expenditures (capex)
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $86,000 | $66,000 | +330.00% |
| Q3 2025 | 2025-09-30 | $24,000 | $5,000 | +26.32% |
| Q2 2025 | 2025-06-30 | $17,000 | — | — |
| Q1 2025 | 2025-03-31 | $11,000 | −$56,000 | −83.58% |
| Q4 2024 | 2024-12-31 | $20,000 | −$336,000 | −94.38% |
| Q3 2024 | 2024-09-30 | $19,000 | −$338,000 | −94.68% |
| Q2 2024 · Jul 9 | 2024-07-09 | $35.1M | $34.8M | +12525.90% |
| Q2 2024 · Jun 30 | 2024-06-30 | $89,000 | −$189,000 | −67.99% |
| Q1 2024 | 2024-03-31 | $67,000 | −$183,000 | −73.20% |
| Q4 2023 | 2023-12-31 | $356,000 | −$264,000 | −42.58% |
| Q3 2023 | 2023-09-30 | $357,000 | −$102,000 | −22.22% |
| Q2 2023 | 2023-06-30 | $278,000 | −$827,000 | −74.84% |
| Q1 2023 | 2023-03-31 | $250,000 | −$92,000 | −26.90% |
| Q4 2022 | 2022-12-31 | $620,000 | $434,000 | +233.33% |
| Q3 2022 | 2022-09-30 | $459,000 | $306,000 | +200.00% |
| Q2 2022 | 2022-06-30 | $1.1M | $1.1M | — |
| Q1 2022 | 2022-03-31 | $342,000 | $328,000 | +2342.86% |
| Q4 2021 | 2021-12-31 | $186,000 | — | — |
| Q3 2021 | 2021-09-30 | $153,000 | — | — |
| Q2 2021 | 2021-06-30 | $0 | — | — |
| Q1 2021 | 2021-03-31 | $14,000 | — | — |
Amylyx Pharmaceuticals capital expenditures (capex) trends
Between the periods ended 2021-12-31 and 2025-12-31, Amylyx Pharmaceuticals's capital expenditures (capex) decreased from $353,000 to $138,000, a change of −$215,000. The latest reported quarter, Q4 2025, shows $86,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals source filings ↗